Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C67H115N21O23S |
| Molecular Weight | 1614.822 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 15 / 15 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O
InChI
InChIKey=GLXYOFXNKBTMQL-YKCHQESGSA-N
InChI=1S/C67H115N21O23S/c1-7-34(4)52(86-55(99)37(17-12-23-74-67(72)73)78-62(106)51(33(2)3)85-54(98)36(70)20-26-112-6)63(107)80-39(16-9-11-22-69)65(109)87-24-13-18-45(87)60(104)75-30-48(92)77-43(31-89)58(102)76-35(5)53(97)81-40(27-47(71)91)56(100)79-38(15-8-10-21-68)64(108)88-25-14-19-46(88)61(105)84-44(32-90)59(103)82-41(28-49(93)94)57(101)83-42(66(110)111)29-50(95)96/h33-46,51-52,89-90H,7-32,68-70H2,1-6H3,(H2,71,91)(H,75,104)(H,76,102)(H,77,92)(H,78,106)(H,79,100)(H,80,107)(H,81,97)(H,82,103)(H,83,101)(H,84,105)(H,85,98)(H,86,99)(H,93,94)(H,95,96)(H,110,111)(H4,72,73,74)/t34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,51-,52-/m0/s1
| Molecular Formula | C67H115N21O23S |
| Molecular Weight | 1614.822 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 15 / 15 |
| E/Z Centers | 5 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:05:43 UTC 2023
by
admin
on
Sat Dec 16 12:05:43 UTC 2023
|
| Record UNII |
3K6A6FJ98O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
613417
Created by
admin on Sat Dec 16 12:05:43 UTC 2023 , Edited by admin on Sat Dec 16 12:05:43 UTC 2023
|
||
|
FDA ORPHAN DRUG |
622517
Created by
admin on Sat Dec 16 12:05:43 UTC 2023 , Edited by admin on Sat Dec 16 12:05:43 UTC 2023
|
||
|
FDA ORPHAN DRUG |
664918
Created by
admin on Sat Dec 16 12:05:43 UTC 2023 , Edited by admin on Sat Dec 16 12:05:43 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3K6A6FJ98O
Created by
admin on Sat Dec 16 12:05:43 UTC 2023 , Edited by admin on Sat Dec 16 12:05:43 UTC 2023
|
PRIMARY | |||
|
134687212
Created by
admin on Sat Dec 16 12:05:43 UTC 2023 , Edited by admin on Sat Dec 16 12:05:43 UTC 2023
|
PRIMARY | |||
|
C95890
Created by
admin on Sat Dec 16 12:05:43 UTC 2023 , Edited by admin on Sat Dec 16 12:05:43 UTC 2023
|
PRIMARY | |||
|
485818-40-4
Created by
admin on Sat Dec 16 12:05:43 UTC 2023 , Edited by admin on Sat Dec 16 12:05:43 UTC 2023
|
PRIMARY | |||
|
PIF-1
Created by
admin on Sat Dec 16 12:05:43 UTC 2023 , Edited by admin on Sat Dec 16 12:05:43 UTC 2023
|
PRIMARY | Human (80119 ) Summary: PIF1 is a 5-prime-to-3-prime DNA helicase that negatively regulates telomerase (see TERT; MIM 187270), a reverse transcriptase that maintains telomere length (Zhang et al., 2006 (PubMed 16522649) |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
SummaryThis gene encodes a DNA-dependent adenosine triphosphate (ATP)-metabolizing enzyme that functions as a 5' to 3' DNA helicase. The encoded protein can resolve G-quadruplex structures and RNA-DNA hybrids at the ends of chromosomes. It also prevents telomere elongation by inhibiting the actions of telomerase. Alternative splicing and the use of alternative start codons results in multiple isoforms that are differentially localized to either the mitochondria or the nucleus. (provided by RefSeq, Nov 2013)
|
